CMS proposes faster prior authorization decisions for drugs

CMS has proposed changes meant to speed up drug prior authorization and reduce paperwork delays. If finalized, the rule would set deadlines for many drug requests and expand electronic prior authorization tools.

The basic idea is straightforward: faster decisions, more digital processing, and more reporting on denials and appeals. But this is still a proposal, not final policy, so the details could change before any requirements take effect.

What CMS is proposing

On April 10, 2026, CMS said the Interoperability Standards and Prior Authorization for Drugs proposed rule would require prior authorization decisions no later than 24 hours for urgent requests and 72 hours for standard requests in many drug cases. The agency also said the proposal would expand electronic prior authorization and increase transparency about denials and appeals outcomes.

CMS said the proposal builds on its 2024 interoperability and prior authorization final rule, which focused on non-drug items and services. The agency is also tying this effort to broader work on electronic prior authorization across the health system.

Who could notice the difference

Patients waiting on medications may be the first to notice any change if decisions come back faster. That could matter for people managing chronic conditions, specialty medications, or treatment changes that depend on timely approval.

Clinicians and office staff could also see more requests handled through electronic systems instead of slower manual workflows. CMS says the goal is to improve data exchange and reduce administrative burden.

Why this matters

Prior authorization has long been a source of delay and frustration in U.S. care. Policy groups such as KFF have noted that the process can be hard for patients and clinicians to navigate, and that data on approvals and denials are often limited.

For everyday readers, the issue is not just paperwork. When approvals take longer, patients may wait longer to start treatment, and families may face more uncertainty about whether a drug will be covered.

What is not settled yet

This is still a proposed rule. CMS can revise the language, deadlines, and implementation details after the public comment process before issuing a final rule.

CMS has also moved ahead separately on electronic prior authorization. On May 13, 2026, the agency announced early adopters for that initiative, which suggests broader momentum toward digital prior authorization tools ahead of future compliance dates.

What readers can do now

If you or a family member is waiting on a medication approval, ask the prescribing office or health plan how the request is being tracked and whether an appeal is available if it is denied or delayed.

It may also help to ask whether supporting records can be sent electronically, since that can reduce back-and-forth in some cases. Plan rules, state requirements, and provider workflows can vary.

For now, the main takeaway is that CMS is trying to speed up drug prior authorization, but patients should not assume the new timelines are already in place. The final rule process will determine what actually changes.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.